CAPE TOWN, SA / ACCESSWIRE / November 1, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
Medspresso™ is pleased to announce its live coffee webinar is scheduled for Friday, 12 November 2021 at 15:00 SAST. The webinar will feature a panel of coffee experts with decades’ worth of experience and expertise in everything from growing, roasting, brewing, and appraising coffee. The panel will dive into the current state of the coffee market and further discuss the art, craft, and science of the bean-to-cup journey and everything in-between. The esteemed panel includes Gerald Charles, Alessandro Morrico, and Michael Sachar, and is chaired by Jeff Robinson.
“Every day, millions of people around the world begin their day with a cup of coffee. Some chug it as vital fuel to get them through their day, and some savor it carefully as part of their morning ritual. For most, coffee is just a drink, but not for us. For us, it’s an art, a craft and a passion. Our devotion to coffee has taken us all over the world in the search for the finest beans. Join us for an exciting conversation exploring the history of coffee, the art of roasting, and a deep dive into the world of specialty coffee.” Michael Sachar explains.
The panel of experts will include award-winning, internationally renowned barista and roaster Gerald Charles from Rock ‘n Roller Coffee. Gerald has been involved in the South African coffee industry for over 18 years and his technical knowledge surrounding coffee and the intricacies of roasting the perfect bean is unparalleled.
Also joining the panel is Alessandro Morrico CEO of Morrico Import Export, a specialist coffee equipment importer, distributor, and coffee consulting company in South Africa. Alessandro holds an SCAE Diploma (Specialty Coffee Association of America and Europe) and is one of very few Q Graders in South Africa, meaning he has mastered the ins and outs of everything coffee. He is Vice Chairman of the Speciality Coffee Association of South Africa (SCASA) and has been Barista Championship Head Judge for over 10 years. He was certified for the World Barista Championship from 2009 to 2011. In short, Alessandro knows his beans.
Michael Sachar, the third panelist and CEO of M2Bio Food and Beverage, possesses an extraordinary amount of experience having worked in the USA, China, and the Middle East trading in raw and roasted coffee beans for 20 years. He has a very keen eye and taste for consumer demands and behavior. Michael will share his knowledge on the health benefits of the CBD and coffee combination, and lift the veil on how coffee enthusiasts can bring the world-class specialty coffee taste and experience into their homes.
To attend the webinar sign up here.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Publicly traded company (OTC Pink: WUHN)
Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
View source version on accesswire.com: